


## Data Sheet

Product Name:	GDC-0077
Cat. No.:	CS-6459
CAS No.:	2060571-02-8
Molecular Formula:	C <sub>18</sub> H <sub>19</sub> F <sub>2</sub> N <sub>5</sub> O <sub>4</sub>
Molecular Weight:	407.37
Target:	Apoptosis; PI3K
Pathway:	Apoptosis; PI3K/Akt/mTOR
Solubility:	DMSO : ≥ 180 mg/mL (441.86 mM)



### BIOLOGICAL ACTIVITY:

GDC-0077 (RG6114) is a potent, orally available, and selective **PI3K $\alpha$**  inhibitor (**IC<sub>50</sub>**=0.038 nM). GDC-0077 (RG6114) exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. GDC-0077 (RG6114) is more selective for mutant versus wild-type PI3K $\alpha$ <sup>[1]</sup>. **IC<sub>50</sub> & Target:** IC<sub>50</sub>: 0.038 nM (PI3K $\alpha$ )<sup>[1]</sup> **In Vitro:** GDC-0077 (RG6114) is >300-fold more selective for PI3K $\alpha$  over the other class I PI3K isoforms ( $\beta$ ,  $\delta$ , and  $\gamma$ ) and >2000-fold more selective over PIK family members. GDC-0077 selectively degrades mutant PI3K $\alpha$  in a proteasome-dependent fashion resulting in reduction of PI3K pathway activity biomarkers such as pAKT and pPRAS40, inhibition of cell proliferation, and increased apoptosis in human PIK3CA-mutant breast cancer cell lines to a greater extent when compared to PIK3CA wild-type cells<sup>[1]</sup>. **In Vivo:** GDC-0077 (p.o.) results in tumor regressions, induction of apoptosis, and a reduction of pAKT, pPRAS40, and pS6RP in a dose-dependent fashion in patient-derived PIK3CA-mutant breast cancer xenograft models<sup>[1]</sup>.

### References:

[1]. R Hong, Abstract PD4-14: GDC-0077 is a selective PI3K $\alpha$  inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium.

### CAIndexNames:

Propanamide, 2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]-, (2S)-

### SMILES:

C[C@@H](C(N)=O)NC1=CC=C(C2=NC(N3[C@H](C(F)F)COC3=O)=CN2CCO4)C4=C1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA